The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ABVX | +892.44% | N/A | N/A | +1,157% |
| S&P | +19.89% | +109.18% | +15.89% | +62% |
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.28M | 0.0% |
| Market Cap | $485.42M | 0.0% |
| Net Income | -$54.92M | 0.0% |
| EBITDA | -$53.70M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $71.54M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $41.94M | 0.0% |
| Short Term Debt | $57.34M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -118.24% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$39.32M | 0.0% |
| Operating Free Cash Flow | -$39.30M | 0.0% |
| Metric | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|
| Price to Book | 9.42 | 11.53 | - |
| Price to Tangible Book Value | 24.57 | 30.08 | - |
| Enterprise Value to EBITDA | -7.62 | -9.55 | - |
| Total Debt | $99.98M | $99.28M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
